| Name | VULM 1457 |
| Description | VULM 1457 is a potent ACAT inhibitor. VULM 1457 has remarkable hypolipidaemic activity and improves the overall myocardial ischaemia-reperfusion injury outcomes. VULM1457 significantly reduces production and secretion of adrenomedullin (AM) and down-regulates AM receptors on human hepatoblastic cells. |
| In vitro | Preincubation of HepG2 cells with VULM1457 (0.1 μM) significantly reduced the specific [125I]AM binding on hypoxic cells with BmaxHypox being 127±10 and KD 0.06±0.11 nM. Preincubation of cells with VULM1457 (0.1 μM) significantly enhanced the number of cells (24.2±6 %) and higher concentrations of VULM1457 (1.0 and 10.0 μM) reduces the total number of cells[2]. In HepG2 cell lines, VULM1457 (0.03 μM; 0.1 μM) significantly down-regulated specific AM receptors on HepG2 cells, and reduced AM secretion of HepG2 cells exposed to hypoxia. VULM1457 negatively regulates cell proliferation induced by AM[2]. |
| In vivo | In male Wistar rats, VULM 1457 protected the hearts of diabetic–hypercholesterolaemic rats against ischemia/reperfusion injury in vivo[1]. VULM 1457 (50 mg/kg/day) significantly decreases plasma total cholesterol levels (1.7±0.1 mM vs. 2.9±0.5 mM in diabetic–hypercholesterolaemic animals). The hypolipidaemic effect of VULM 1457 is also observed in the liver of DM-HCH rats (3.9±0.2 mg/g vs. 7.4±1.0 mg/g)[1]. |
| Storage | Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | DMSO : 60 mg/mL (133.46 mM), Sonication is recommended.
|
| Keywords | VULM-1457 | VULM1457 | VULM 1457 | myocardial | mono- acylglycerol acyltransferase | ischaemia-reperfusion | Inhibitor | inhibit | hypolipidaemic | hypercholesterolaemia | Diglyceride acyltransferase | Diacylglycerol acyltransferase | diabetes mellitus | cholesterol acyltransferase | Acyltransferase | acyl-CoA:cholesterol acyltransferase | acyl-CoA | ACAT |
| Inhibitors Related | Xanthohumol | Lecimibide | OSMI-3 | 2,2'-Methylenebis(6-tert-butyl-4-methylphenol) | Cyclandelate | Eldacimibe | YM17E | 2-Furoic acid | RU-SKI 43 | Eflucimibe | PF-04620110 | DGAT-1 inhibitor 2 |
| Related Compound Libraries | Bioactive Compound Library | Anti-Diabetic Compound Library | Inhibitor Library | Lipid Metabolism Compound Library | Metabolism Compound Library | Bioactive Compounds Library Max |
United States
